Preliminary observations indicate variable patterns of plasma 5-fluorouracil (5-FU) levels during dose optimization of infusional 5-FU in colorectal cancer patients

Cancer Biology and Therapy

Volumn 12, Issue 7, 2011, Pages 557-568

  Kline, Christina Leah ^a   Sheikh, Hassan S ^a   Scicchitano, Angelique ^a   Gingrich, Rebecca ^a   Beachler, Cheryl ^a   Finnberg, Niklas K ^a   Liao, Jason ^a   Sivik, Jeffrey ^a   El Deiry, Wafik S ^a  

^a PENN STATE CANCER INSTITUTE   (United States)

Author keywords

5 FU AUC; Chemotherapy; Colorectal cancer; FOLFOX; OnDose; Pharmacokinetic monitoring

Indexed keywords

B RAF KINASE; BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; K RAS PROTEIN; MESSENGER RNA; OXALIPLATIN; THYMIDYLATE SYNTHASE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; COLORECTAL CANCER; CONTINUOUS INFUSION; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG METABOLISM; FEMALE; GENE MUTATION; HUMAN; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; RECOMMENDED DRUG DOSE;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; LEUCOVORIN; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; THYMIDYLATE SYNTHASE;

EID: 80053410222     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.12.7.18059     Document Type: Article

References (47)

1. Schuell B, Gruenberger T, Kornek GV, Dworan N, Depisch D, Lang F, et al. Side effects during chemotherapy predict tumour response in advanced colorectal cancer. Br J Cancer 2005; 93:744-8; PMID:16160693; http://dx.doi.org/10.1038/sj. bjc.6602783.
2. Gamelin E, Delva R, Jacob J, Merrouche Y, Raoul JL, Pezet D, et al. Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer. J Clin Oncol 2008; 26:2099-105; PMID:18445839; http://dx.doi.org/10.1200/JCO.2007.13.3934.
3. Gamelin E, Boisdron-Celle M, Delva R, Regimbeau C, Cailleux PE, Alleaume C, et al. Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients. J Clin Oncol 1998; 16:1470-8; PMID:9552054.
4. Gamelin EC, Danquechin-Dorval EM, Dumesnil YF, Maillart PJ, Goudier MJ, Burtin PC, et al. Relationship between 5-fluorouracil (5-FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FU. Cancer 1996; 77:441- 51; PMID:8630950; http://dx.doi.org/10.1002/ (SICI)1097-0142(19960201)77:3<441::AIDCNCR4>3. 0.CO;2-N.
5. Wenstrup R, Saam J, Kaldate R, Rhode M, Hamilton S, Eisenbraun A, et al. Extensive 5-FU inter-patient pharmacokinetic variability may result in suboptimal 5-FU dosing of metastatic and adjuvant colon cancer patients on FOLFOX regimens. ASCO-GI, 2010.
6. Gamelin E, Capitain O, Morel A, et al. Comparison of two patient cohorts treated in parallel for advanced colorectal cancer with a simplified FOLFOX 4 regimen with or without 5-FU therapeutic dose management. ASCO 2009 Gastrointestinal Tumors Symposium, 2009.
7. Ychou M, Duffour J, Kramar A, Debrigode C, Gourgou S, Bressolle F, et al. Individual 5-FU dose adaptation in metastatic colorectal cancer: results of a phase II study using a bimonthly pharmacokinetically intensified LV5FU2 regimen. Cancer Chemother Pharmacol 2003; 52:282-90; PMID:12827293; http:// dx.doi.org/10.1007/s00280-003-0658-0.
8. Saif MW, Choma A, Salamone SJ, Chu E. Pharmacokinetically guided dose adjustment of 5-fluorouracil: a rational approach to improving therapeutic outcomes. J Natl Cancer Inst 2009; 101:1543-52; PMID:19841331; http://dx.doi.org/10.1093/jnci/djp328.
9. Ensminger WD, Rosowsky A, Raso V, Levin DC, Glode M, Come S, et al. A clinical-pharmacological evaluation of hepatic arterial infusions of 5-fluoro- 2'-deoxyuridine and 5-fluorouracil. Cancer Res 1978; 38:3784-92; PMID:151583.
10. Wagner JG, Gyves JW, Stetson PL, Walker-Andrews SC, Wollner IS, Cochran MK, et al. Steady-state nonlinear pharmacokinetics of 5-fluorouracil during hepatic arterial and intravenous infusions in cancer patients. Cancer Res 1986; 46:1499-506; PMID:3943107.
11. Obrecht JP, Weber W, Cano JP, Crevoisier C, Alberto P, Forgo I, et al. 5-Fluorouracil: a comparative pharmacokinetic study and preliminary results of a clinical phase I study. Recent Results Cancer Res 1981; 79:101-7; PMID:7302355.
12. Naguib FN, el Kouni MH, Cha S. Enzymes of uracil catabolism in normal and neoplastic human tissues. Cancer Res 1985; 45:5405-12; PMID:3931905.
13. Zhang X, Diasio RB. Regulation of human dihydropyrimidine dehydrogenase: implications in the pharmacogenetics of 5-FU-based chemotherapy. Pharmacogenomics 2007; 8:257-65; PMID:17324113; http://dx.doi.org/10.2217/ 14622416.8.3.257.
14. van Kuilenburg AB, van Lenthe H, Blom MJ, Mul EP, van Gennip AH. Profound variation in dihydropyrimidine dehydrogenase activity in human blood cells: major implications for the detection of partly deficient patients. Br J Cancer 1999; 79:620- 6; PMID:10027339; http://dx.doi.org/10.1038/ sj.bjc.6690097.
15. Mauritz R, van Groeningen CJ, Smid K, Jansen G, Pinedo HM, Peters GJ. Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression after administration of 5-fluorouracil to patients with colorectal cancer. Int J Cancer 2007; 120:2609- 12; PMID:17330233; http://dx.doi.org/10.1002/ ijc.22626.
16. McLeod HL, Sludden J, Hardy SC, Lock RE, Hawksworth GM, Cassidy J. Autoregulation of 5-fluorouracil metabolism. Eur J Cancer 1998; 34:1623-7; PMID:9893640; http://dx.doi.org/10.1016/S0959- 8049(98)00175-0.
17. Kashima N, Ueda M, Kanazawa J. Effect of 5-fluorouracil and epidermal growth factor on cell growth and dihydropyrimidine dehydrogenase regulation in human uterine cervical carcinoma SKG-IIIb cells. Cancer Sci 2003; 94:821-5; PMID:12967482; http://dx.doi. org/10.1111/j.1349-7006.2003.tb01525.x.
18. Sakurai Y, Uraguchi T, Imazu H, Hasegawa S, Matsubara T, Ochiai M, et al. Changes in thymidylate synthase and its inhibition rate and changes in dihydropyrimidine dehydrogenase after the administration of 5-fluorouracil with cisplatin to nude mice with gastric cancer xenograft SC-1-NU. Gastric Cancer 2004; 7:110-6; PMID:15224198; http://dx.doi.org/10.1007/ s10120-004-0280-9.
19. Harris BE, Song R, Soong SJ, Diasio RB. Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 1990; 50:197-201; PMID:2293556.
20. Friberg G, Schumm P, Ratain MJ, Schilsky RL, Fleming GF. Circadian variations in plasma 5-fluorouracil (5-FU) levels during 24-hour infusions. Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition), 2004:2055.
21. Zhu AX, Puchalski TA, Stanton VP Jr., Ryan DP, Clark JW, Nesbitt S, et al. Dihydropyrimidine dehydrogenase and thymidylate synthase polymorphisms and their association with 5-fluorouracil/leucovorin chemotherapy in colorectal cancer. Clin Colorectal Cancer 2004; 3:225-34; PMID:15025795; http:// dx.doi.org/10.3816/CCC.2004.n.003.
22. Milano G, Etienne MC, Cassuto-Viguier E, Thyss A, Santini J, Frenay M, et al. Influence of sex and age on fluorouracil clearance. J Clin Oncol 1992; 10:1171-5; PMID:1607921.
23. Port RE, Daniel B, Ding RW, Herrmann R. Relative importance of dose, body surface area, sex, and age for 5-fluorouracil clearance. Oncology 1991; 48:277-81; PMID:1891168; http://dx.doi. org/10.1159/000226942.
24. Stein BN, Petrelli NJ, Douglass HO, Driscoll DL, Arcangeli G, Meropol NJ. Age and sex are independent predictors of 5-fluorouracil toxicity. Analysis of a large scale phase III trial. Cancer 1995; 75:11-7; PMID:7804963; http://dx.doi. org/10.1002/1097-0142(19950101)75:1<11::AIDCNCR2820750104> 3.0.CO;2-N.
25. Bertino J, Gamelin E, Milano G. 5-Fluorouracil drug management: Pharmacokinetics and Pharmacogenomics workshop meeting summary. 5-Fluorouracil drug management Pharmacokinetics and Pharmacogenomics workshop meeting summary Orlando, Florida: Clinical Colorectal Cancer, 2007.
26. Rothenberg ML, Oza AM, Bigelow RH, Berlin JD, Marshall JL, Ramanathan RK, et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracilleucovorin: interim results of a phase III trial. J Clin Oncol 2003; 21:2059-69; PMID:12775730; http:// dx.doi.org/10.1200/JCO.2003. 11.126.
27. De Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18:2938-47; PMID:10944126.
28. Maindrault-Goebel F, Louvet C, Andre T, Carola E, Lotz JP, Molitor JL, et al. Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR. Eur J Cancer 1999; 35:1338-42; PMID:10658524; http://dx.doi. org/10.1016/S0959-8049(99)00149-5.
29. Alnaim L. Individualization of 5-Fluorouracil in the Treatment of Colorectal Cancer. SRX Pharmacology 2010; 2010.
30. Shimizu T, Satoh T, Tamura K, Ozaki T, Okamoto I, Fukuoka M, et al. Oxaliplatin/fluorouracil/leucovorin (FOLFOX4 and modified FOLFOX6) in patients with refractory or advanced colorectal cancer: post-approval Japanese population experience. Int J Clin Oncol 2007; 12:218-23; PMID:17566846; http://dx.doi. org/10.1007/s10147-007-0658-x.
31. Tournigand C, Cervantes A, Figer A, Lledo G, Flesch M, Buyse M, et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer-a GERCOR study. J Clin Oncol 2006; 24:394- 400; PMID:16421419; http://dx.doi.org/10.1200/ JCO.2005.03.0106.
32. Boisdron-Celle M, Craipeau C, Brienza S, Delva R, Guerin-Meyer V, Cvitkovic E, et al. Influence of oxaliplatin on 5-fluorouracil plasma clearance and clinical consequences. Cancer Chemother Pharmacol 2002; 49:235-43; PMID:11935216; http://dx.doi. org/10.1007/s00280-001-0406-2.
33. Capitain O, Asevoaia A, Boisdron-Celle M, Poirier AL, Maillart P, Morel A, et al. Influence of pharmacogenetic polymorphisms on 5-fluorouracil and irinotecan efficacy and tolerance in patients treated for advanced colorectal cancer. ASCO 2008 Gastrointestinal Cancers Symposum, 2008.
34. Saam J, Critchfield GC, Hamilton SA, Roa BB, Wenstrup RJ, Kaldate RR. Body surface area-based dosing of 5-fluorouracil results in extensive interindividual variability in 5-fluorouracil exposure in colorectal cancer patients on FOLFOX regimens. Clinical Colorectal Cancer 2011.
35. Ibrahim T, Di Paolo A, Amatori F, Mercatali L, Ravaioli E, Flamini E, et al. Time-dependent pharmacokinetics of 5-fluorouracil and association with treatment tolerability in the adjuvant setting of colorectal cancer. J Clin Pharmacol 2011; PMID:21383342.
36. Gusella M, Frigo AC, Bolzonella C, Marinelli R, Barile C, Bononi A, et al. Predictors of survival and toxicity in patients on adjuvant therapy with 5-fluorouracil for colorectal cancer. Br J Cancer 2009; 100:1549- 57; PMID:19384296; http://dx.doi.org/10.1038/ sj.bjc.6605052.
37. Malet-Martino M, Martino R. Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review. Oncologist 2002; 7:288-323; PMID:12185293; http://dx.doi.org/10.1634/theoncologist. 7-4-288.
38. Blakley RL, Ramasastri BV, McDougall BM. The Biosynthesis of Thymidylic Acid. V. Hydrogen Isotope Studies with Dihydrofolic Reductase and Thymidylate Synthetase. J Biol Chem 1963; 238:3075-9; PMID:14081927.
39. Langenbach RJ, Danenberg PV, Heidelberger C. Thymidylate synthetase: mechanism of inhibition by 5-fluoro-2′-deoxyuridylate. Biochem Biophys Res Commun 1972; 48:1565-71; PMID:4263280; http:// dx.doi.org/10.1016/0006-291X(72) 90892-3.
40. Santi DV, Pena VA, Lam SS. On the structure of the cofactor in the complex formed with thymidylate synthetase, 5,10-methylenetetrahy-drofolate and 5-fluoro- 2′-deoxyuridylate. Biochim Biophys Acta 1976; 438:324-31; PMID:938684.
41. Leichman CG, Lenz HJ, Leichman L, Danenberg K, Baranda J, Groshen S, et al. Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol 1997; 15:3223-9; PMID:9336359.
42. Edler D, Glimelius B, Hallstrom M, Jakobsen A, Johnston PG, Magnusson I, et al. Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracilbased chemotherapy. J Clin Oncol 2002; 20:1721- 8; PMID:11919227; http://dx.doi.org/10.1200/ JCO.2002.07.039.
43. Shirota Y, Stoehlmacher J, Brabender J, Xiong YP, Uetake H, Danenberg KD, et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 2001; 19:4298-304; PMID:11731512.
44. Aschele C, Debernardis D, Casazza S, Antonelli G, Tunesi G, Baldo C, et al. Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy. J Clin Oncol 1999; 17:1760-70; PMID:10561213.
45. Cascinu S, Aschele C, Barni S, Debernardis D, Baldo C, Tunesi G, et al. Thymidylate synthase protein expression in advanced colon cancer: correlation with the site of metastasis and the clinical response to leucovorin- modulated bolus 5-fluorouracil. Clin Cancer Res 1999; 5:1996-9; PMID:10473077.
46. Horie N, Aiba H, Oguro K, Hojo H, Takeishi K. Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5′-terminal regulatory region of the human gene for thymidylate synthase. Cell Struct Funct 1995; 20:191-7; PMID:7586009; http://dx.doi.org/10.1247/csf.20.191.
47. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003; 3:330-8; PMID:12724731; http:// dx.doi.org/10.1038/nrc1074.